Extended-dose DOAC vs full-dose DOAC #Renove trial #ASH24 Late breaking abstract. Officially, reduced dose was not non-inferior, but recurrent #VTE rates were low and there is a substantial reduction in major and non-major bleeding. Congratulations to the French colleagues of #Innovte!
December 10, 2024 at 4:27 PM
🎉Congratulations Francis and the 🇫🇷 INNOVTE team for the RENOVE study that will be presented at ASH 2024 @ash-hematology.bsky.social as a Late-Breaking Abstract !
💊Reduced- Vs Full dose of DOAC for long terme anticoagulation after VTE ⤵️
ash.confex.com/ash/2024/web...
💊Reduced- Vs Full dose of DOAC for long terme anticoagulation after VTE ⤵️
ash.confex.com/ash/2024/web...
Paper: Extended Treatment of Venous Thromboembolism with Reduced- Vs Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence
ash.confex.com
November 27, 2024 at 3:32 PM
🎉Congratulations Francis and the 🇫🇷 INNOVTE team for the RENOVE study that will be presented at ASH 2024 @ash-hematology.bsky.social as a Late-Breaking Abstract !
💊Reduced- Vs Full dose of DOAC for long terme anticoagulation after VTE ⤵️
ash.confex.com/ash/2024/web...
💊Reduced- Vs Full dose of DOAC for long terme anticoagulation after VTE ⤵️
ash.confex.com/ash/2024/web...
Le service de l’AP-HM est ainsi : centre d’excellence européen en HTA, centre de compétence des maladies artérielles rares, et fait partie du réseau F-CRIN INNOVTE (Investigation Network On Venous Thrombo-Embolism).
March 27, 2024 at 5:09 PM
Le service de l’AP-HM est ainsi : centre d’excellence européen en HTA, centre de compétence des maladies artérielles rares, et fait partie du réseau F-CRIN INNOVTE (Investigation Network On Venous Thrombo-Embolism).